Researchers are adapting CAR T-cell therapy, originally developed for cancer treatment, to treat autoimmune diseases such as lupus, multiple sclerosis (MS), and rheumatoid arthritis.
The approach works by collecting a patient’s T cells and genetically modifying them to target and destroy overactive B cells, which are responsible for mistakenly attacking healthy tissues in autoimmune conditions. The goal is to reset the immune system in a single treatment, potentially removing the need for long-term medication.
Early research suggests this strategy may not only stop disease progression but could also help restore some lost function, especially in conditions like MS. The team is also exploring similar approaches for other autoimmune diseases, along with related cell-based therapies already used in certain severe cases.
This shift toward “immune resetting” could transform treatment for millions of people with autoimmune disorders by moving from symptom management to long-term or possibly curative solutions.